Umeclidinium Brm/Vilanterol Tr
Average cost per year*
Average cost per beneficiary*
This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems. NOTE: This is a summary and does NOT have all possible information about this product. This information does not assure that this product is safe, effective, or appropriate for you. This information is not individual medical advice and does not substitute for the advice of your health care professional. Always ask your health care professional for complete information about this product and your specific health needs.
*Origin of the terms and chart data used within this page: https://data.cms.gov/
Yes, Anoro Ellipta is covered by Medicare.
In 2021, the average cost per dose of Anoro Ellipta was $7.46.
The average dose of Anoro Ellipta received per year is 109,260,943 units
338,712 Medicare beneficiaries received Anoro Ellipta in 2021, which was a -0.1% from 2020
There were 1,593,170 claims made by Medicare beneficiaries, which is a -0.13% from 2020
The average spending amount per claim in 2021 was $572.68
The average Medicare spending per beneficiary amount for Anoro Ellipta was $2,693.65
Glaxosmithkline received $912,370,401.83
The total amount spent on Anoro Ellipta by Medicare is $912,370,401.83
Short Term Medical Insurance
Limited Fixed Indemnity Plans